{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:52:50Z","timestamp":1791575570985,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00862-x","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T14:40:19Z","timestamp":1738161619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Musculoskeletal adverse events associated with CDK4\/6 inhibitors: a real-world study using FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhenlin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"862_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb4184","volume":"15","author":"M Malumbres","year":"2014","unstructured":"Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014;15:1\u201310.","journal-title":"Genome Biol"},{"issue":"6","key":"862_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 2022;22(6):356\u201372.","journal-title":"Nat Rev Cancer"},{"issue":"6577","key":"862_CR3","doi-asserted-by":"publisher","first-page":"eabc1495","DOI":"10.1126\/science.abc1495","volume":"375","author":"A Fassl","year":"2022","unstructured":"Fassl A, Geng Y, Sicinski P. CDK4 and CDK6 kinases: from basic science to cancer therapy. Science. 2022;375(6577):eabc1495.","journal-title":"Science"},{"issue":"2","key":"862_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3390\/cancers13020332","volume":"13","author":"M Roberto","year":"2021","unstructured":"Roberto M, Astone A, Botticelli A, et al. CDK4\/6 inhibitor treatments in patients with hormone receptor positive, Her2 negative advanced breast cancer: potential molecular mechanisms, clinical implications and future perspectives. Cancers. 2021;13(2):332.","journal-title":"Cancers"},{"issue":"7","key":"862_CR5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904\u201315.","journal-title":"Lancet Oncol"},{"issue":"11","key":"862_CR6","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3390\/cancers11111661","volume":"11","author":"V Rossi","year":"2019","unstructured":"Rossi V, Berchialla P, Giannarelli D, et al. Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4\/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials. Cancers. 2019;11(11):1661.","journal-title":"Cancers"},{"issue":"10","key":"862_CR7","doi-asserted-by":"publisher","first-page":"e2021062","DOI":"10.1001\/jamanetworkopen.2020.21062","volume":"3","author":"JM Martin","year":"2020","unstructured":"Martin JM, Goldstein LJ. In support of CDK4\/6 inhibitors\u2014a meta-analysis of available randomized data. JAMA Netw Open. 2020;3(10):e2021062\u20132021062.","journal-title":"JAMA Netw Open"},{"key":"862_CR8","doi-asserted-by":"crossref","unstructured":"Goetz MP, Toi M, Klise S, Frenzel M, Bourayou N, Di Leo A. MONARCH 3: a randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4\/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC). Am Soc Clin Oncol. 2015.","DOI":"10.1200\/jco.2015.33.15_suppl.tps624"},{"issue":"2","key":"862_CR9","first-page":"42","volume":"9","author":"A Andrikopoulou","year":"2021","unstructured":"Andrikopoulou A, Fiste O, Apostolidou K, et al. CDK4\/6 inhibitors and Arthralgia: a single Institution experience. Med Sci. 2021;9(2):42.","journal-title":"Med Sci"},{"issue":"3","key":"862_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/cancers13030465","volume":"13","author":"A Andrikopoulou","year":"2021","unstructured":"Andrikopoulou A, Fiste O, Liontos M, Dimopoulos M-A, Zagouri F. Aromatase and CDK4\/6 inhibitor-induced musculoskeletal symptoms: a systematic review. Cancers. 2021;13(3):465.","journal-title":"Cancers"},{"issue":"24","key":"862_CR11","doi-asserted-by":"publisher","first-page":"9509","DOI":"10.3390\/ijerph17249509","volume":"17","author":"A Marcian\u00f2","year":"2020","unstructured":"Marcian\u00f2 A, Guzzo GM, Peditto M, Picone A, Oteri G. Medication-related osteonecrosis of the Jaws and CDK4\/6 inhibitors: a recent association. Int J Environ Res Public Health. 2020;17(24):9509.","journal-title":"Int J Environ Res Public Health"},{"key":"862_CR12","doi-asserted-by":"publisher","first-page":"797157","DOI":"10.3389\/fonc.2022.797157","volume":"12","author":"A Botticelli","year":"2022","unstructured":"Botticelli A, Fabbri A, Roberto M, et al. The role of the CDK4\/6 inhibitor ribociclib in locally advanced and oligometastatic hormone receptor positive, Her2 negative, advanced breast cancer: case series and review of the literature. Front Oncol. 2022;12:797157.","journal-title":"Front Oncol"},{"key":"862_CR13","doi-asserted-by":"crossref","unstructured":"Skafida E, Andrikopoulou A, Terpos E, et al. Impact of CDK4\/6 inhibitors on aromatase inhibitor-associated musculoskeletal syndrome (AIMSS) in the adjuvant setting. Breast J. 2023;2023:3614296.","DOI":"10.1155\/2023\/3614296"},{"issue":"2","key":"862_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10549-022-06518-2","volume":"192","author":"CC Conley","year":"2022","unstructured":"Conley CC, McIntyre M, Pensak NA, et al. Barriers and facilitators to taking CDK4\/6 inhibitors among patients with metastatic breast cancer: a qualitative study. Breast Cancer Res Treat. 2022;192(2):385\u201399.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"862_CR15","first-page":"172","volume":"1","author":"K Anand","year":"2019","unstructured":"Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting System (FAERS). Cardio Oncol. 2019;1(2):172\u20138.","journal-title":"Cardio Oncol"},{"key":"862_CR16","doi-asserted-by":"publisher","first-page":"663088","DOI":"10.3389\/fphar.2021.663088","volume":"12","author":"Z Ma","year":"2021","unstructured":"Ma Z, Pei J, Sun X, et al. Pericardial toxicities associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2021;12:663088.","journal-title":"Front Pharmacol"},{"issue":"7","key":"862_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796.","journal-title":"Int J Med Sci"},{"issue":"18","key":"862_CR18","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.3390\/ijms21186479","volume":"21","author":"M Piezzo","year":"2020","unstructured":"Piezzo M, Cocco S, Caputo R, et al. Targeting cell cycle in breast cancer: CDK4\/6 inhibitors. Int J Mol Sci. 2020;21(18):6479.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"862_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47(6):585\u201399.","journal-title":"Drug Saf"},{"key":"862_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JGO.19.11000","volume":"5","author":"S-A Im","year":"2019","unstructured":"Im S-A, Mukai H, Park IH, et al. Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study. J Global Oncol. 2019;5:1\u201319.","journal-title":"J Global Oncol"},{"issue":"10","key":"862_CR21","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942\u201350.","journal-title":"N Engl J Med"},{"key":"862_CR22","doi-asserted-by":"publisher","first-page":"693104","DOI":"10.3389\/fonc.2021.693104","volume":"11","author":"MA George","year":"2021","unstructured":"George MA, Qureshi S, Omene C, Toppmeyer DL, Ganesan S. Clinical and pharmacologic differences of CDK4\/6 inhibitors in breast cancer. Front Oncol. 2021;11:693104.","journal-title":"Front Oncol"},{"issue":"1","key":"862_CR23","doi-asserted-by":"publisher","first-page":"113275","DOI":"10.1016\/j.yexcr.2022.113275","volume":"420","author":"D Mademtzoglou","year":"2022","unstructured":"Mademtzoglou D, Relaix F. From cyclins to CDKIs: cell cycle regulation of skeletal muscle stem cell quiescence and activation. Exp Cell Res. 2022;420(1):113275.","journal-title":"Exp Cell Res"},{"issue":"6","key":"862_CR24","doi-asserted-by":"publisher","first-page":"e108946","DOI":"10.15252\/embj.2021108946","volume":"41","author":"B Wang","year":"2022","unstructured":"Wang B, Varela-Eirin M, Brandenburg SM, et al. Pharmacological CDK4\/6 inhibition reveals a p53\u2010dependent senescent state with restricted toxicity. EMBO J. 2022;41(6):e108946.","journal-title":"EMBO J"},{"issue":"2","key":"862_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.tips.2015.10.004","volume":"37","author":"ML Schmitz","year":"2016","unstructured":"Schmitz ML, Kracht M. Cyclin-dependent kinases as coregulators of inflammatory gene expression. Trends Pharmacol Sci. 2016;37(2):101\u201313.","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"862_CR26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41584-021-00652-9","volume":"17","author":"Z Szekanecz","year":"2021","unstructured":"Szekanecz Z, McInnes IB, Schett G, Szamosi S, Benk\u0151 S, Sz\u0171cs G. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585\u201395.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"862_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","volume":"21","author":"CE Onesti","year":"2021","unstructured":"Onesti CE, Jerusalem G. CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Rev Anticancer Ther. 2021;21(3):283\u201398.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"862_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3322\/caac.21184","volume":"63","author":"GK Dy","year":"2013","unstructured":"Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. Cancer J Clin. 2013;63(4):249\u201379.","journal-title":"Cancer J Clin"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00862-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00862-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00862-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T14:40:22Z","timestamp":1738161622000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00862-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["862"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00862-x","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}